Clinical Trial

A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered alone and in combination with an antiemetic medication, ondansetron, in participants living with overweight or obesity.
Trial Details
NCT Number NCT07310563
Lead Sponsor Amgen
Conditions Overweight, Obesity
Enrollment 59 participants
Start Date 2024-12-10
Primary Completion 2025-05-09 (estimated)
Study Completion 2025-05-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-30